Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland’s 20 largest listed companies, market operator SIX said on Tuesday.
Information about any other changes to SMI and Switzerland’s other indexes will be released later, the bourse said.
Novartis last year announced the spin off of Alcon to the Basel drugmaker’s shareholders in the first half of this year.
Bank Vontobel analysts have said Alcon could be worth between $15 billion and $23 billion, adding its ongoing recovery would influence the final price.
By John Revill
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.